Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in NF2-Related Schwannomatosis
NCT07707947Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in Neurofibromatosis type 2-related schwannomatosis (NF2), sponsored by Beijing Tiantan Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
Neurofibromatosis type 2-related schwannomatosis (NF2)
Beyond the preview
Go deeper on NCT07707947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707947.